Non-CFC metered dose inhalers: the patent landscape

Area of Science:

• Pharmaceutical Sciences
• Intellectual Property Law
• Chemical Engineering

Background:

• The pharmaceutical industry is navigating a significant shift in respiratory drug delivery devices.
• Transitioning metered dose inhalers (MDIs) from chlorofluorocarbon (CFC) propellants to non-CFC alternatives presents complex challenges.
• Numerous patent applications have been filed at the European Patent Office (EPO) concerning this propellant transition.

Purpose of the Study:

• To analyze patent activity related to the transition of pressurized metered dose inhalers (MDIs) away from CFC propellants.
• To identify key areas of innovation and potential patentability challenges in non-CFC MDI development.
• To understand the landscape of patent oppositions and their implications for market entry.

Main Methods:

• Review of European Patent Office (EPO) application data over the past decade.
• Categorization of patents based on innovation type (formulation, drug-specific, manufacturing, container/closure).
• Analysis of patent opposition trends and grounds (primarily obviousness).

Main Results:

• A substantial volume of patent applications has been submitted concerning non-CFC MDIs.
• Innovations span various aspects, including new formulations, specific drug applications, manufacturing processes, and device modifications.
• A significant number of these patents have faced opposition, often citing obviousness.

Conclusions:

• The transition to non-CFC MDIs has spurred considerable patenting activity, reflecting innovation in respiratory medicine.
• Patent oppositions highlight the rigorous scrutiny applied to new MDI technologies.
• The full scope of valid patents and their impact on the market is still emerging due to lengthy opposition proceedings.